Intended for healthcare professionals

Clinical & scientific information

Epithrive® is an oral nutritional supplement providing targeted nutritional support as an adjunct to standard wound care. This page is prepared to support clinical judgement. It is not a substitute for the approved product label.

01 · Composition

Composition per 24 g sachet

Contains fish. Marine collagen peptides are fish-derived. Not suitable for anyone with a known fish or seafood allergy. Verify the allergen declaration on the approved label.

Amino acids, peptides & metabolites

L-Arginine7 g
L-Glutamine7 g
Marine collagen peptides (fish-derived)2.5 g
Calcium β-hydroxy-β-methylbutyrate (Ca-HMB)1.5 g

Amino-acid & peptide load ~17 g per sachet — provided as an aid to protein-load assessment (e.g. renal or hepatic patients), not as a declared protein value.

Vitamins

Vitamin A (preformed retinol)750 mcg
Vitamin C60 mg
Vitamin E7.5 mg
Vitamin B3 (niacinamide)10.5 mg
Vitamin B61.43 mg
Vitamin B121.65 mcg

Minerals

Zinc13 mg
Copper1.3 mg
Selenium30 mcg
Calcium (elemental)200 mg

Orange-flavoured powder for oral reconstitution; no added sugar. Single-use 24 g sachet, 10 sachets per box.

02 · Rationale

Nutritional rationale

Tissue repair raises the body's demand for protein, specific amino acids and several vitamins and trace elements, while intake and absorption are frequently reduced by illness, age, hospitalisation or comorbidity. Malnutrition and micronutrient depletion are common in chronic and surgical wounds and are recognised in clinical nutrition guidance as factors associated with delayed healing.

L-Arginine

Substrate for nitric oxide and proline synthesis pathways.

L-Glutamine

Fuel substrate for enterocytes and immune cells.

Collagen peptides

Source of glycine, proline and hydroxyproline.

Vitamin C

Cofactor for collagen hydroxylase enzymes.

Zinc & copper

Enzyme cofactors relevant to protein synthesis and connective-tissue cross-linking.

Ca-HMB

Leucine metabolite studied in relation to muscle protein balance.

These are recognised nutrient functions describing the rationale for the formulation. They are not, individually or collectively, a claim that Epithrive® heals wounds, and they do not substitute for outcome evidence generated with the finished product.

03 · Evidence

Evidence & scientific basis

Evidence relevant to Epithrive® falls into two tiers, which should not be conflated.

Tier 1 · Published

Peer-reviewed literature examines arginine, glutamine, HMB, collagen hydrolysate and combination amino-acid formulations in wound healing and surgical recovery, including systematic-review and meta-analysis evidence. Authors frequently note that included trials were small, of variable methodological quality and of low certainty. The published combination-formula studies were conducted with a differently composed commercial product. This literature supports the scientific rationale for the Epithrive® formulation; it does not demonstrate that Epithrive® reproduces those outcomes.

Tier 2 · Real-world case series

De-identified real-world case reports, with serial clinician documentation and before/after imaging, are held on file and available to registered healthcare professionals through the clinical resources below. These are uncontrolled observations recorded alongside continued standard wound care and are described further in the case-report section.

04 · Safety

Safety information & directions for use

Full HCP information (PDF) Complete quantitative composition, contraindications, warnings and drug–nutrient guidance

Contraindications

  • Known hypersensitivity to any ingredient, including fish-derived marine collagen peptides.
  • Diagnosed hypervitaminosis A (contains preformed vitamin A).

Use only under medical supervision

  • Chronic kidney disease (Stage 3–5) — individualise; assess protein, calcium, preformed vitamin A and trace elements.
  • Pregnancy / breastfeeding — insufficient data; obstetrician approval required.
  • Hepatic impairment — nitrogen load requires assessment.

Full renal, hepatic, special-population, drug–nutrient and tolerability detail is set out in the HCP information PDF above.

05 · Resources

Clinical resources & dossier

Registered healthcare professionals

Access the clinical dossier — formulation rationale, ingredient-level evidence, de-identified real-world case series with before/after imaging, and clinician documentation.

Intended for registered healthcare professionals. Proprietary material — please do not redistribute.

Continue to clinical resources
06 · Case reports

Real-world case reports

The following are illustrative de-identified case reports in which Epithrive® was used as an adjunct to standard wound care. Full clinical detail, serial imaging and clinician documentation are in the gated clinical resources above.

Diabetic foot ulcer

Chronic ulcer of the great toe

  • PatientAdult, type 2 diabetes mellitus
  • WoundPressure ulcer of the great toe (Grade II–III), present over a year
  • UseOne sachet daily, adjunct to ongoing standard wound care

Serial clinician review documented progressive granulation, reducing exudate, margin contraction and epithelialisation over the observation period, alongside continued local wound care.

Individual case report — an uncontrolled single-patient observation recorded alongside standard wound care. Not a controlled study; not representative of expected or typical results. Causation cannot be established from a single case, and no healing timeline should be inferred.

Wagner Grade II DFU

Stalled post-debridement wound

  • PatientAdult male, type 2 diabetes mellitus
  • WoundPost-debridement wound of the little toe following infection; healing had stalled despite surgery and dressings
  • UseOne sachet daily, added as adjunct to continued standard wound care and insulin therapy

Serial review documented a cleaner wound bed, healthy granulation and progression through the proliferative phase to margin contraction, with no further surgical intervention required during the observation period.

Individual case report — an uncontrolled single-patient observation recorded alongside standard wound care and insulin therapy. Not a controlled study; not representative of expected or typical results. Causation cannot be established from a single case, and no healing timeline should be inferred.

07 · Education

Articles & education

Evidence-based articles on nutrition in wound care, available in multiple languages on the Epithrive® education hub.

Visit the education hub learn.epithrive.in — nutrition & wound-care articles

Medical enquiries & adverse-event reporting

For full quantitative composition, medical enquiries or to report a suspected adverse event:

info@zenfitra.com · +91 93261 21131

Nuin Wellness Pvt. Ltd. (ZenFitra Lifesciences Division), Pune, Maharashtra · FSSAI 11524998000214

Epithrive® is a health supplement / nutraceutical licensed under the Food Safety and Standards Act, 2006. It is not a drug and is not intended to diagnose, treat, cure or prevent any disease. It is intended as adjunctive nutritional support only and does not replace standard wound care, glycaemic control, infection management, debridement, off-loading, compression, vascular assessment or any other medically indicated treatment. Not for use as a sole source of nutrition. Do not exceed the recommended daily intake. Use under the guidance of a qualified healthcare professional. Keep out of reach of children.